Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease

Detalhes bibliográficos
Autor(a) principal: Magalhães,Carolina A.
Data de Publicação: 2015
Outros Autores: Figueiró,Micheli, Fraga,Vanessa G., Mateo,Elvis C., Toledo,André A. S. F., Carvalho,Maria das Graças, Caramelli,Paulo, Gomes,Karina B.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442015000600376
Resumo: ABSTRACT Introduction: Several studies have been conducted in order to validate cerebrospinal fluid biomarkers for the diagnosis of Alzheimer’s disease (AD), aiming primarily to facilitate the early diagnosis. Objective: To evaluate CSF biomarkers on patients with probable AD and the applicability of the international references values in this population. Methods: 46 individuals were recruited and classified as probable AD (n = 19), mild cognitive impairment (MCI) (n = 5) and other dementias (n = 22). The cerebrospinal fluid (CSF) biomarkers were measured using the INNOTEST kits for enzyme-linked immunosorbent assay (ELISA). Higher Tau protein values and lower Aβand Innotest Amyloid Tau Index (IATI) values were observed in AD group when compared with MCI; higher levels of Tau and phosphorylated Tau (P-Tau), and lower Aβand IATI values were observed in AD group when compared to patients with other dementias. No biomarker or IATI was able to distinguish between MCI and other dementias. The kappa index between biomarkers and the clinical diagnosis was regular to Tau and IATI, and weak to Aβand P-tau. Conclusion: The cut-off values for each biomarker that showed better combined sensibility and specificity differ from the reference values suggested by the manufacturer. The CSF biomarkers represent important resources that can help with the AD diagnosis, although the results interpretation must be made based on the analysis of the three analytes together. The cut-off values must be established to address the specificities and characteristics of each population.
id SBP-1_4866e154b5d5aa051ab0c7bf09844c67
oai_identifier_str oai:scielo:S1676-24442015000600376
network_acronym_str SBP-1
network_name_str Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
repository_id_str
spelling Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s diseaseamyloidtau proteinsAlzheimer’s diseasecerebrospinal fluidABSTRACT Introduction: Several studies have been conducted in order to validate cerebrospinal fluid biomarkers for the diagnosis of Alzheimer’s disease (AD), aiming primarily to facilitate the early diagnosis. Objective: To evaluate CSF biomarkers on patients with probable AD and the applicability of the international references values in this population. Methods: 46 individuals were recruited and classified as probable AD (n = 19), mild cognitive impairment (MCI) (n = 5) and other dementias (n = 22). The cerebrospinal fluid (CSF) biomarkers were measured using the INNOTEST kits for enzyme-linked immunosorbent assay (ELISA). Higher Tau protein values and lower Aβand Innotest Amyloid Tau Index (IATI) values were observed in AD group when compared with MCI; higher levels of Tau and phosphorylated Tau (P-Tau), and lower Aβand IATI values were observed in AD group when compared to patients with other dementias. No biomarker or IATI was able to distinguish between MCI and other dementias. The kappa index between biomarkers and the clinical diagnosis was regular to Tau and IATI, and weak to Aβand P-tau. Conclusion: The cut-off values for each biomarker that showed better combined sensibility and specificity differ from the reference values suggested by the manufacturer. The CSF biomarkers represent important resources that can help with the AD diagnosis, although the results interpretation must be made based on the analysis of the three analytes together. The cut-off values must be established to address the specificities and characteristics of each population.Sociedade Brasileira de Patologia Clínica2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442015000600376Jornal Brasileiro de Patologia e Medicina Laboratorial v.51 n.6 2015reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)instname:Sociedade Brasileira de Patologia (SBP)instacron:SBP10.5935/1676-2444.20150059info:eu-repo/semantics/openAccessMagalhães,Carolina A.Figueiró,MicheliFraga,Vanessa G.Mateo,Elvis C.Toledo,André A. S. F.Carvalho,Maria das GraçasCaramelli,PauloGomes,Karina B.eng2015-12-03T00:00:00Zoai:scielo:S1676-24442015000600376Revistahttp://www.scielo.br/jbpmlhttps://old.scielo.br/oai/scielo-oai.php||jbpml@sbpc.org.br1678-47741676-2444opendoar:2015-12-03T00:00Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)false
dc.title.none.fl_str_mv Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
title Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
spellingShingle Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
Magalhães,Carolina A.
amyloid
tau proteins
Alzheimer’s disease
cerebrospinal fluid
title_short Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
title_full Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
title_fullStr Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
title_full_unstemmed Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
title_sort Cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer’s disease
author Magalhães,Carolina A.
author_facet Magalhães,Carolina A.
Figueiró,Micheli
Fraga,Vanessa G.
Mateo,Elvis C.
Toledo,André A. S. F.
Carvalho,Maria das Graças
Caramelli,Paulo
Gomes,Karina B.
author_role author
author2 Figueiró,Micheli
Fraga,Vanessa G.
Mateo,Elvis C.
Toledo,André A. S. F.
Carvalho,Maria das Graças
Caramelli,Paulo
Gomes,Karina B.
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Magalhães,Carolina A.
Figueiró,Micheli
Fraga,Vanessa G.
Mateo,Elvis C.
Toledo,André A. S. F.
Carvalho,Maria das Graças
Caramelli,Paulo
Gomes,Karina B.
dc.subject.por.fl_str_mv amyloid
tau proteins
Alzheimer’s disease
cerebrospinal fluid
topic amyloid
tau proteins
Alzheimer’s disease
cerebrospinal fluid
description ABSTRACT Introduction: Several studies have been conducted in order to validate cerebrospinal fluid biomarkers for the diagnosis of Alzheimer’s disease (AD), aiming primarily to facilitate the early diagnosis. Objective: To evaluate CSF biomarkers on patients with probable AD and the applicability of the international references values in this population. Methods: 46 individuals were recruited and classified as probable AD (n = 19), mild cognitive impairment (MCI) (n = 5) and other dementias (n = 22). The cerebrospinal fluid (CSF) biomarkers were measured using the INNOTEST kits for enzyme-linked immunosorbent assay (ELISA). Higher Tau protein values and lower Aβand Innotest Amyloid Tau Index (IATI) values were observed in AD group when compared with MCI; higher levels of Tau and phosphorylated Tau (P-Tau), and lower Aβand IATI values were observed in AD group when compared to patients with other dementias. No biomarker or IATI was able to distinguish between MCI and other dementias. The kappa index between biomarkers and the clinical diagnosis was regular to Tau and IATI, and weak to Aβand P-tau. Conclusion: The cut-off values for each biomarker that showed better combined sensibility and specificity differ from the reference values suggested by the manufacturer. The CSF biomarkers represent important resources that can help with the AD diagnosis, although the results interpretation must be made based on the analysis of the three analytes together. The cut-off values must be established to address the specificities and characteristics of each population.
publishDate 2015
dc.date.none.fl_str_mv 2015-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442015000600376
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442015000600376
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/1676-2444.20150059
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv
Sociedade Brasileira de Patologia Clínica
publisher.none.fl_str_mv
Sociedade Brasileira de Patologia Clínica
dc.source.none.fl_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial v.51 n.6 2015
reponame:Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
instname:Sociedade Brasileira de Patologia (SBP)
instacron:SBP
instname_str Sociedade Brasileira de Patologia (SBP)
instacron_str SBP
institution SBP
reponame_str Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
collection Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
repository.name.fl_str_mv Jornal Brasileiro de Patologia e Medicina Laboratorial (Online) - Sociedade Brasileira de Patologia (SBP)
repository.mail.fl_str_mv ||jbpml@sbpc.org.br
_version_ 1752122296337694720